Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Tizanidine

Catalog No. T7065 Copy Product Info
Purity: 99.11%
😃Good
Tizanidine, an α2-adrenergic receptor agonist, suppresses the release of neurotransmitters from central nervous system (CNS) noradrenergic neurons.

Tizanidine

Copy Product Info
😃Good
Catalog No. T7065

Tizanidine, an α2-adrenergic receptor agonist, suppresses the release of neurotransmitters from central nervous system (CNS) noradrenergic neurons.

Tizanidine
Cas No. 51322-75-9
Pack SizePriceUSA StockGlobal StockQuantity
5 mg$30In StockIn Stock
10 mg$48In StockIn Stock
25 mg$67In StockIn Stock
50 mg$88In StockIn Stock
100 mg$108In StockIn Stock
500 mg$266In StockIn Stock
1 mL x 10 mM (in DMSO)$39In StockIn Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.11%
Appearance:Solid
Color:Yellow
Contact us for more batch information

Resource Download

Product Introduction

Tizanidine AI Summary
Tizanidine is a biologically active compound with diverse pharmacokinetic and pharmacodynamic properties. It has a partition coefficient (LogD6.5) of -0.68 and a delta logD of -0.81 between pH 6.5 and 7.4. The compound’s ionization constant (pKa) is 8.0, reflecting its ionization behavior. It demonstrates moderate oral bioavailability in humans at 49%, alongside high solubility at pH 7.4 (600 μM) and pH 7.2 (18,250 μg/mL). In terms of distribution and clearance, Tizanidine has a volume of distribution at steady state (Vdss) of 2.4 L/kg and high binding to plasma proteins with a fraction unbound (Fu) of 0.7. It shows a total body clearance of 11.0 mL/min/kg and a renal clearance of 0.33 mL/min/kg, indicating significant renal excretion and suggesting efficient clearance from the body. The hepatic clearance is low at 10.7 mL/min/kg. Tizanidine displays bioactivity at several targets. It displaces [125I]PIC from human alpha2 adrenoceptors and human imidazoline receptor 1, with Ki values of 117.9 nM and 28.31 nM respectively, and a selectivity ratio of 0.6197 favoring imidazoline receptor 1. It also inhibits human FAAH at 1 μM concentration, demonstrating 7.43% inhibition. Additionally, it inhibits a range of enzymes and receptors, including moderate inhibition of SARS-CoV-2 3CL-Pro protease and binding activities towards various adrenergic and histamine receptors. Pharmacodynamically, Tizanidine shows efficacy as an agonist at alpha-2A and alpha-2C adrenergic receptors, inhibiting forskolin-stimulated cAMP accumulation with an EC50 of 86.0 nM for alpha-2A. It presents antiviral activity against SARS-CoV-2 and demonstrated moderate inhibition of induced cytotoxicity in VERO-6 cells at a concentration of 10 μM. However, Tizanidine is also associated with significant hepatotoxic effects, as evidenced by elevated liver enzymes such as ALT, AST, and others. It can induce conditions like cholelithiasis, cirrhosis, hepatic failure, and hepatitis, suggesting a need for caution in its therapeutic use. Overall, Tizanidine represents a multi-faceted pharmaceutical agent with notable pharmacological actions and potential bioactivities against various biological targets, but caution is warranted due to its association with liver toxicity..
Note: Summary generated by AI. Data source: ChEMBL
Bioactivity
Description
Tizanidine, an α2-adrenergic receptor agonist, suppresses the release of neurotransmitters from central nervous system (CNS) noradrenergic neurons.
Chemical Properties
Molecular Weight253.71
FormulaC9H8ClN5S
Cas No.51322-75-9
SmilesN(C=1C=2C(C=CC1Cl)=NSN2)C=3NCCN3
Relative Density.1.82 g/cm3
Storage & Solubility Information
Storagekeep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 4.4 mg/mL (17.34 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.94 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.9415 mL19.7075 mL39.4151 mL197.0754 mL
5 mM0.7883 mL3.9415 mL7.8830 mL39.4151 mL
10 mM0.3942 mL1.9708 mL3.9415 mL19.7075 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Tizanidine | purchase Tizanidine | Tizanidine cost | order Tizanidine | Tizanidine chemical structure | Tizanidine formula | Tizanidine molecular weight